BioSpace News Archive

Days after the Cambridge-based company halted its BACE inhibitor program for Alzheimer’s disease, the company stopped another clinical trial in idiopathic pulmonary fibrosis due to safety reasons.

Are you worried about your first phone interview? Don’t worry, everyone gets through that phase. Follow these phone interview tips to nail your telephonic interview.

Late Monday the federal government charged the husband and wife team of Yu Zhou, 49, and Li Chen, 46, with theft of scientific trade secrets from the hospital that focused on exosomes and exosome isolation.

A stigma remains around lung cancer and many people still regard the disease as something of a self-inflicted ailment. But that stigma is waning, new research conducted by the Inova Schar Cancer Institute and Genentech shows.

Acceleron Pharma said the Phase II FSHD trial assessing the efficacy of ACE-083 did not achieve functional secondary endpoints during the study.

Collaborating researchers at the University of Iowa and Capital Medical University in Beijing, China, found that a drug used to treat enlarged prostate, terazosin, appears able to slow the progress of Parkinson’s disease.

The trial is still ongoing, but met its primary endpoint of ASAS40.

The two companies also inked a commercial licensing deal for Bayer to use One Drop’s platform in Bayer’s worldwide bio-digital efforts in oncology, cardiovascular disease and women’s health.

Professionals have unprecedented opportunities today to become known, and the biggest opportunity comes from building an online presence.

Heparin Sodium Injection in a ready-to-use syringe is the first product using Hikma’s new injectable manufacturing capability [17-September-2019] LONDON , Sept. 17, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P) the multinational pharmaceutical company, has l